Literature DB >> 16123351

Characterization of susceptibility of inbred mouse strains to diabetic nephropathy.

Zhonghua Qi1, Hiroki Fujita, Jianping Jin, Linda S Davis, Yihan Wang, Agnes B Fogo, Matthew D Breyer.   

Abstract

Differential susceptibility to diabetic nephropathy has been observed in humans, but it has not been well defined in inbred strains of mice. The present studies characterized the severity of diabetic nephropathy in six inbred mouse strains including C57BL/6J, DBA/2J, FVB/NJ, MRL/MpJ, A/J, and KK/HlJ mice. Diabetes mellitus was induced using low-dose streptozotocin injection. Progression of renal injury was evaluated by serial measurements of urinary albumin excretion, glomerular filtration rate (GFR), and terminal assessment of renal morphology over 25 weeks. Despite comparable levels of hyperglycemia, urinary albumin excretion and renal histopathological changes were dramatically different among strains. DBA/2J and KK/HlJ mice developed significantly more albuminuria than C57BL/6J, MRL/MpJ, and A/J mice. Severe glomerular mesangial expansion, nodular glomerulosclerosis, and arteriolar hyalinosis were observed in diabetic DBA/2J and KK/HlJ mice. Glomerular hyperfiltration was observed in all diabetic strains studied except A/J. The significant decline in GFR was not evident over the 25-week period of study, but diabetic DBA/2J mice exhibited a tendency for GFR to decline. Taken together, these results indicate that differential susceptibility to diabetic nephropathy exists in inbred mice. DBA/2J and KK/HlJ mice are more prone to diabetic nephropathy, whereas the most widely used C57BL/6J mice are relatively resistant to development of diabetic nephropathy.

Entities:  

Mesh:

Year:  2005        PMID: 16123351     DOI: 10.2337/diabetes.54.9.2628

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  141 in total

1.  Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Andrew Advani; Qingling Huang; Kerri Thai; Suzanne L Advani; Kathryn E White; Darren J Kelly; Darren A Yuen; Kim A Connelly; Philip A Marsden; Richard E Gilbert
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.

Authors:  Tobias B Huber; Christopher Kwoh; Hui Wu; Katsuhiko Asanuma; Markus Gödel; Björn Hartleben; Ken J Blumer; Jeffrey H Miner; Peter Mundel; Andrey S Shaw
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

3.  A susceptibility gene for kidney disease in an obese mouse model of type II diabetes maps to chromosome 8.

Authors:  Streamson Chua; Yifu Li; Shun Mei Liu; Ruijie Liu; Ka Tak Chan; Jeremiah Martino; Zongyu Zheng; Katalin Susztak; Vivette D D'Agati; Ali G Gharavi
Journal:  Kidney Int       Date:  2010-06-02       Impact factor: 10.612

4.  Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone.

Authors:  Jeffry S Nyman; Jesse L Even; Chan-Hee Jo; Erik G Herbert; Matthew R Murry; Gael E Cockrell; Elizabeth C Wahl; R Clay Bunn; Charles K Lumpkin; John L Fowlkes; Kathryn M Thrailkill
Journal:  Bone       Date:  2010-12-23       Impact factor: 4.398

5.  Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney.

Authors:  Dilip K Deb; Riyue Bao; Yan Chun Li
Journal:  FASEB J       Date:  2017-02-01       Impact factor: 5.191

6.  Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.

Authors:  Weier Qi; Hillary A Keenan; Qian Li; Atsushi Ishikado; Aimo Kannt; Thorsten Sadowski; Mark A Yorek; I-Hsien Wu; Samuel Lockhart; Lawrence J Coppey; Anja Pfenninger; Chong Wee Liew; Guifen Qiang; Alison M Burkart; Stephanie Hastings; David Pober; Christopher Cahill; Monika A Niewczas; William J Israelsen; Liane Tinsley; Isaac E Stillman; Peter S Amenta; Edward P Feener; Matthew G Vander Heiden; Robert C Stanton; George L King
Journal:  Nat Med       Date:  2017-04-24       Impact factor: 53.440

7.  Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice.

Authors:  S Ghosh; M Khazaei; F Moien-Afshari; L S Ang; D J Granville; C B Verchere; S R Dunn; P McCue; A Mizisin; K Sharma; I Laher
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

8.  Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c.

Authors:  Byoung Geun Han; Chuan-Ming Hao; Elena E Tchekneva; Ying-Ying Wang; Chieh Allen Lee; Benyamin Ebrahim; Raymond C Harris; Timothy S Kern; David H Wasserman; Matthew D Breyer; Zhonghua Qi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

9.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

10.  The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Luciano Adorini; Mark Pruzanski; Frank J Gonzalez; Pnina Scherzer; Linda Lewis; Shinobu Miyazaki-Anzai; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.